Tango's Drug Combo Worked In 11 Of 12 Pancreatic Cancer Patients In An Early Trial

Pancreatic cancer is one of the toughest diseases in medicine. New drugs almost always come up short. Most patients have few good options, and survival rates have stayed low for years. So when a small biotech posts numbers like these, Wall Street pays attention fast. Tango Therapeutics ran an early trial of its drug combo. It shrank tumors in 11 of 12 pancreatic cancer patients. The stock shot higher on the news.

What The Trial Showed

Tango's drug is called vopimetostat. In the study, it was paired with a drug from Revolution Medicines.

The headline number is a 92% response rate. That is just the share of patients whose tumors got smaller. In this cancer, that figure is usually tiny. Pancreatic tumors are famously hard to shrink. So a 92% rate turned heads.

Two more numbers stood out too. Nine in ten patients had not gotten worse after six months. Every patient in the group saw their disease held in check. Doctors said the benefit also looked durable. That means it lasted. It was not just a quick blip. Most side effects were mild, which matters just as much.

The early lung cancer group looked strong too. All three patients there responded. There was also a second pancreatic combo. It used a different partner drug. That one got a 52% response rate. The trial has treated 59 patients so far. No one quit the study because of side effects.

We turn stories like this into plain-English money terms every morning in Market Briefs. Joining gets you a free investing masterclass too.

Why Investors Are Watching

Tango's drug only works in cancers missing a gene called MTAP. That sounds narrow. But it covers about 40% of all pancreatic cancers.

The drug goes after one weak spot in the tumor. It does not blast the whole body with chemo. That is the kind of targeted approach the cancer-drug market has chased for years. Tango's chief said the early results were very encouraging. The company even framed the goal as a possible chemo-free option.

Still, early data is just early data. Tango is a small company. So each result moves its stock a lot. Small groups can look great and then fade in bigger trials. That is one reason biotech is one of the most volatile corners of the market.

What To Watch

Tango plans to move the combo into a Phase 3 trial. That is the last stage before a drug can ask for approval. It hopes to lock the design later this year. First, it needs regulators to weigh in. More data is also due in the months ahead. The full picture will take time to emerge. For now, the early read is unusually good. A bigger trial is the only way to know for sure.

The science cleared a bar that almost nothing clears here. The next bar is much bigger.

For the market read on biotech and beyond, sign up for Market Briefs here. You also get a free 45-minute course on finding investments.